/ CompletedNot Applicable [Translation] Study on the bioequivalence of bilastine oral solution in healthy volunteers
主要目的:本试验旨在研究健康受试者单次空腹口服深圳市贝美药业有限公司研制的比拉斯汀口服溶液(120 mL:0.3 g)的药代动力学特征;以 Faes Farma, S.A. 持证的比拉斯汀片(Bilaxten®,20 mg)为参比制剂,比较两制剂中药动学参数 Cmax、AUC0-t、AUC0-∞,评价两制剂的人体生物等效性。
次要目的:观察受试制剂和参比制剂在健康受试者中的安全性。
[Translation] Primary objective: This study aims to study the pharmacokinetic characteristics of a single fasting oral administration of bilastine oral solution (120 mL: 0.3 g) developed by Shenzhen Beimei Pharmaceutical Co., Ltd. in healthy subjects; using the bilastine tablets (Bilaxten®, 20 mg) certified by Faes Farma, S.A. as the reference preparation, to compare the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two preparations, and to evaluate the bioequivalence of the two preparations in humans.
Secondary objective: To observe the safety of the test preparation and the reference preparation in healthy subjects.
/ CompletedNot Applicable 舒他西林干混悬剂在健康受试者中的单次给药、随机、开放、两周期、双交叉、餐后状态下的生物等效性研究
[Translation] A single-dose, randomized, open-label, two-period, double-crossover, fed-state bioequivalence study of sultamicillin dry suspension in healthy volunteers
主要研究目的:以PFIZER PHARMA PFE GmbH持证,Haupt Pharma Latina S.r.l. Latina生产的舒他西林干混悬剂(商品名:Unacid®;规格:375 mg/7.5 ml)为参比制剂,以成都锦华药业有限责任公司生产的舒他西林干混悬剂(规格:5.0 g/瓶)为受试制剂,通过单中心、随机、开放、单次给药、两周期、双交叉临床研究来评价两种制剂在餐后状态下的人体生物等效性。
次要研究目的:观察受试制剂和参比制剂在健康受试者中的安全性。
[Translation] The main purpose of the study is to use the sultamicillin dry suspension (trade name: Unacid®; specification: 375 mg/7.5 ml) produced by Haupt Pharma Latina S.r.l. Latina and licensed by PFIZER PHARMA PFE GmbH as the reference preparation and the sultamicillin dry suspension (specification: 5.0 g/bottle) produced by Chengdu Jinhua Pharmaceutical Co., Ltd. as the test preparation to evaluate the bioequivalence of the two preparations in the human body under the fed state through a single-center, randomized, open, single-dose, two-period, double-crossover clinical study.
Secondary purpose of the study: to observe the safety of the test preparation and the reference preparation in healthy subjects.
/ CompletedNot Applicable 舒他西林干混悬剂在健康受试者中的单次给药、随机、开放、两周期、双交叉、空腹及餐后状态下的生物等效性研究
[Translation] A single-dose, randomized, open-label, two-period, double-crossover bioequivalence study of sultamicillin dry suspension in healthy volunteers under fasting and fed conditions
主要研究目的:以PFIZER PHARMA PFE GmbH持证,Haupt Pharma Latina S.r.l. Latina生产的舒他西林干混悬剂(商品名:Unacid®;规格:375 mg/7.5 ml)为参比制剂,以成都锦华药业有限责任公司生产的舒他西林干混悬剂(规格:5.0 g/瓶)为受试制剂,通过单中心、随机、开放、单次给药、两周期、双交叉临床研究来评价两种制剂在空腹及餐后状态下的人体生物等效性。
次要研究目的:观察受试制剂和参比制剂在健康受试者中的安全性。
[Translation] The main purpose of the study is to use the sultamicillin dry suspension (trade name: Unacid®; specification: 375 mg/7.5 ml) produced by Haupt Pharma Latina S.r.l. Latina and licensed by PFIZER PHARMA PFE GmbH as the reference preparation and the sultamicillin dry suspension (specification: 5.0 g/bottle) produced by Chengdu Jinhua Pharmaceutical Co., Ltd. as the test preparation to evaluate the bioequivalence of the two preparations in the fasting and postprandial state through a single-center, randomized, open, single-dose, two-period, double-crossover clinical study.
Secondary purpose of the study: to observe the safety of the test preparation and the reference preparation in healthy subjects.
100 Clinical Results associated with Shenzhen Beimei Pharmaceutical Co., Ltd.
0 Patents (Medical) associated with Shenzhen Beimei Pharmaceutical Co., Ltd.
100 Deals associated with Shenzhen Beimei Pharmaceutical Co., Ltd.
100 Translational Medicine associated with Shenzhen Beimei Pharmaceutical Co., Ltd.